Long-term results of the AIEOP LNH-97 protocol for childhood lymphoblastic lymphoma.

Abstract:

BACKGROUND:Treatment intensification was considered a suitable strategy to increase the cure rate of lymphoblastic lymphoma (LBL) in children. PROCEDURE:The AIEOP LNH-97 trial was run between 1997 and 2007 for newly diagnosed LBL in patients aged less than 18 years. Treatment schedule was based on the previous, LSA2-L2 derived, AIEOP LNH-92 protocol. Modifications included: increased dose of upfront cyclophosphamide and methotrexate, use of l-Asparaginase during induction therapy, intensive block therapy for slow responders, and late intensification ("Reinduction") for patients with advanced stage disease. Total therapy duration was 12 months for stage I and II, and 24 months for stage III and IV. Central nervous system prophylaxis did not include cranial irradiation. RESULTS:114 eligible patients were enrolled, 84 males and 30 females; median age was 9 years. Complete remission was obtained in 98% of patients. After a median follow-up time of seven years, 29 patients failed due to progression of disease (n = 2), relapse (n = 25), or second malignancy (n = 2). The 7-year overall survival was 82% (standard error [SE] 4%) and the 7-year event-free survival was 74% (SE 4%). No subgroup showed significantly different event free survival. None of the patients died of front line chemotherapy-related toxicity. CONCLUSIONS:Treatment intensification was associated with good outcome in children and adolescents with LBL, with limited toxicity. Prognosis after relapse was better for patients who underwent allogeneic hematopoietic stem cell transplantation. Measurements of biological markers and treatment response are necessary for achieving further improvement through more accurate identification and stratification of patients at risk of disease relapse.

journal_name

Pediatr Blood Cancer

journal_title

Pediatric blood & cancer

authors

Pillon M,Aricò M,Mussolin L,Carraro E,Conter V,Sala A,Buffardi S,Garaventa A,D'Angelo P,Lo Nigro L,Santoro N,Piglione M,Lombardi A,Porta F,Cesaro S,Moleti ML,Casale F,Mura R,d'Amore ES,Basso G,Rosolen A

doi

10.1002/pbc.25469

subject

Has Abstract

pub_date

2015-08-01 00:00:00

pages

1388-94

issue

8

eissn

1545-5009

issn

1545-5017

journal_volume

62

pub_type

临床试验,杂志文章
  • Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy.

    abstract:BACKGROUND:A desperate need for novel therapies in pediatric ependymoma (EPN) exists, as chemotherapy remains ineffective and radiotherapy often fails. EPN have significant infiltration of immune cells, which correlates with outcome. Immune checkpoint inhibitors provide an avenue for new treatments. This study characte...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.26960

    authors: Witt DA,Donson AM,Amani V,Moreira DC,Sanford B,Hoffman LM,Handler MH,Levy JMM,Jones KL,Nellan A,Foreman NK,Griesinger AM

    更新日期:2018-05-01 00:00:00

  • Recommendations for medical care in the pediatric oncology camp setting: Consensus statements based on Delphi methodology.

    abstract::For many children with cancer, participation in oncology camp programs is an important component of healing that offers opportunities for fun and can have substantial impacts on social and physical well-being. Optimal medical care and infectious screening for children attending oncology camp is critical to maximize sa...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.28107

    authors: Alexander S,Science M,Breakey V,Clarke A,Gibson P

    更新日期:2020-03-01 00:00:00

  • Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.

    abstract:BACKGROUND:As pegylated asparaginase is becoming the preferred first-line asparaginase preparation in the chemotherapy regimens of childhood acute lymphoblastic leukemia (ALL), there is a need to evaluate this treatment. METHODS:The aim of this study was to evaluate the pharmacokinetics of prolonged upfront biweekly P...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/pbc.26686

    authors: Tram Henriksen L,Gottschalk Højfeldt S,Schmiegelow K,Frandsen TL,Skov Wehner P,Schrøder H,Klug Albertsen B,Nordic Society of Pediatric Hematology and Oncology, NOPHO Group.

    更新日期:2017-12-01 00:00:00

  • Cost-effectiveness of treatment of childhood acute lymphoblastic leukemia with chemotherapy only: the influence of new medication and diagnostic technology.

    abstract:BACKGROUND:Survival for childhood acute lymphoblastic leukemia (ALL) has reached 80-90%. Future improvement in treatment success will involve new technologies and medication, adding to the pressure on limited financial resources. Therefore a retrospective cost-effectiveness analysis of ALL treatment with chemotherapy o...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.23197

    authors: van Litsenburg RR,Uyl-de Groot CA,Raat H,Kaspers GJ,Gemke RJ

    更新日期:2011-12-01 00:00:00

  • Comparison of allergic reactions to pegasparaginase given intravenously versus intramuscularly.

    abstract:BACKGROUND:Pegasparaginase (PEG) is important for treatment of Acute Lymphoblastic Leukemia (ALL). Despite conjugation to polyethylene glycol to reduce immunogenicity, allergic reactions still occur and may be severe. Traditionally, PEG is given via intramuscular (IM) injection but recent protocols have shown it can be...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.23380

    authors: Pidaparti M,Bostrom B

    更新日期:2012-09-01 00:00:00

  • Bevacizumab for symptomatic radiation-induced tumor enlargement in pediatric low grade gliomas.

    abstract:BACKGROUND:Radiation therapy (RT)-induced effects in children treated for low grade glioma (LGG) can result in worsening of neurologic symptoms and clinical and radiographic deterioration. Treatment for radiation-induced tumor enlargement is based on symptom control and usually involves steroids. PROCEDURE:We conducte...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.25277

    authors: Foster KA,Ares WJ,Pollack IF,Jakacki RI

    更新日期:2015-02-01 00:00:00

  • Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate.

    abstract:BACKGROUND:Recent studies suggest that SLCO1B1 c.521T > C variant decreases the clearance of methotrexate (MTX) and elevates its plasma concentration, hence leucovorin doses may need to be adjusted. However, high leucovorin doses may affect the cure rate in childhood acute lymphoblastic leukemia (ALL). Hitherto neither...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.25191

    authors: Zhang HN,He XL,Wang C,Wang Y,Chen YJ,Li JX,Niu CH,Gao P

    更新日期:2014-12-01 00:00:00

  • Hepatoblastoma in a child with neurofibromatosis type I.

    abstract::A major hallmark of NF1 is the development of benign tumors, including peripheral neurofibromas, plexiform neurofibromas, gliomas of the optic tract, other low grade gliomas, and pheochromocytomas. Hepatoblastoma have not been previously reported in patients with neurofibromatosis type 1. We present a case of a 9-mont...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.20663

    authors: Uçar C,Calişkan U,Toy H,Günel E

    更新日期:2007-09-01 00:00:00

  • Langerhans cell histiocytosis masquerading as tuberculosis: a diagnostic dilemma resulting in inappropriate anti-tubercular therapy.

    abstract::Langerhans cell histiocytosis is known to mimic many other conditions. We present two patients where anti-tubercular therapy was instituted when clinical and radiological features suggested tuberculosis. The correct diagnosis of histiocytosis was reached only on further work-up including immunohistochemistry following...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.21930

    authors: Sharma P,Dhingra KK,Sural S,Mandal AK,Singh T

    更新日期:2009-07-01 00:00:00

  • Optic pathway gliomas.

    abstract::Optic pathway gliomas represent approximately 5% of all pediatric intracranial tumors. While these tumors are most frequently low grade astrocytomas, they follow a highly variable clinical course, and accordingly, there is much debate regarding their optimal management. Their propensity to occur in very young children...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,评审

    doi:10.1002/pbc.20655

    authors: Jahraus CD,Tarbell NJ

    更新日期:2006-05-01 00:00:00

  • Medulloblastoma in childhood: Impact of radiation technique upon the outcome of treatment.

    abstract:BACKGROUND:Medulloblastoma is an infratentorial primitive neuroectodermal tumour, diagnosed in paediatric population. The radiotherapy is an essential method of treatment for these tumours. The impact of technical quality of radiation therapy on survival was recently considered. In this study treatment-related variable...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.10401

    authors: Chojnacka M,Skowrońska-Gardas A

    更新日期:2004-02-01 00:00:00

  • Treatment and outcome of patients with thoracic tumors of the Ewing sarcoma family: A report from the Cooperative Weichteilsarkom Studiengruppe CWS-81, -86, -91, -96, and -2002P trials.

    abstract:BACKGROUND:Ewing tumors are the most frequent malignant tumors of the chest wall in children and young adults. Surgical management of these tumors can be challenging. Optimal local control remains controversial. The aim of this study was to analyze treatment, outcome, and surgical procedures in patients with thoracic t...

    journal_title:Pediatric blood & cancer

    pub_type: 更正并重新发布的文章,杂志文章

    doi:10.1002/pbc.27884

    authors: Seitz G,Urla C,Sparber-Sauer M,Schuck A,Vokuhl C,Blank B,Klingebiel T,Kazanowska B,Fuchs J,Koscielniak E

    更新日期:2019-08-01 00:00:00

  • Impact of psychiatric diagnoses on hospital length of stay in children with sickle cell anemia.

    abstract:BACKGROUND:Patients with sickle cell anemia (SCA) experience a broad range of psychiatric disorders, placing them at risk for more complicated and longer hospitalizations for vaso-occlusive crises (VOC). The current study examined the frequency of psychiatric disorders in SCA patients (ages birth to 20 years) admitted ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.23117

    authors: Myrvik MP,Campbell AD,Davis MM,Butcher JL

    更新日期:2012-02-01 00:00:00

  • Transfusion related iron overload in pediatric oncology patients treated at a tertiary care centre and treatment with chelation therapy.

    abstract::We conducted a retrospective chart review to determine prevalence of, risk factors for, and liver toxicity associated with Transfusion Related Iron Overload (TRIO) in pediatric cancer patients, and report our experience with Iron Chelation Therapy (ICT). Total number of transfusions was identified as the major risk fa...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.25189

    authors: Sait S,Zaghloul N,Patel A,Shah T,Iacobas I,Calderwood S

    更新日期:2014-12-01 00:00:00

  • The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: a Children's Oncology Group study.

    abstract:BACKGROUND:The presence of central nervous system (CNS) disease in pediatric acute myeloid leukemia (AML) is often thought to confer a worse prognosis. This study examined the outcome of children with AML who had CNS disease at diagnosis. METHODS:Patients enrolled on Children's Cancer Group protocols 2861, 2891, 2941,...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.22511

    authors: Johnston DL,Alonzo TA,Gerbing RB,Lange BJ,Woods WG

    更新日期:2010-09-01 00:00:00

  • A single-center experience with undifferentiated embryonal sarcoma of the liver.

    abstract::Undifferentiated embryonal sarcoma of the liver (UESL) is a rare aggressive mesenchymal pediatric tumor. Previously, reported outcomes have been very poor. Here, we report a single-center experience of five patients with UESL treated with upfront gross total resection and adjuvant chemotherapy. We have a median follow...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.26154

    authors: Mathias MD,Ambati SR,Chou AJ,Slotkin EK,Wexler LH,Meyers PA,Magnan H

    更新日期:2016-12-01 00:00:00

  • Protocol-based treatment for children with cancer in low income countries in Latin America: a report on the recent meetings of the Monza International School of Pediatric Hematology/Oncology (MISPHO)--part II.

    abstract::Pediatric cancer programs in low-income countries (LIC) can improve outcomes. However, treatment must be tailored to the patient's living conditions and the availability of supportive care. In some cases, a more intense regimen will decrease survival since the increase in death from toxicity may exceed any decrease in...

    journal_title:Pediatric blood & cancer

    pub_type:

    doi:10.1002/pbc.20989

    authors: Howard SC,Ortiz R,Baez LF,Cabanas R,Barrantes J,Fu L,Peña A,Samudio A,Vizcaino M,Rodríguez-Galindo C,Barr RD,Conter V,Biondi A,Masera G,MISPHO Consortium Writing Committee.

    更新日期:2007-04-01 00:00:00

  • The perfect storm: Torsades de Pointes in a child with leukemia.

    abstract::Torsades de Pointes (TdP) is a life-threatening ventricular arrhythmia that can be associated with metabolic abnormalities, exposure to arrhythmogenic medications, and congenital long-QT syndrome. This report describes a patient with ALL and multiple complications of therapy who developed TdP. The patient had no evide...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.20712

    authors: Bagatell R,Hainstock M,Lowe MC,Barber BJ,Samson RA

    更新日期:2007-12-01 00:00:00

  • Assessment of Financial Burden as a Standard of Care in Pediatric Oncology.

    abstract::Family financial hardship has emerged as a burden of pediatric cancer treatment with negative implications for family well-being. As part of an extensive project to create evidence-based standards for the psychosocial care of children with cancer, we performed a literature review of pediatric cancer-associated financi...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,评审

    doi:10.1002/pbc.25714

    authors: Pelletier W,Bona K

    更新日期:2015-12-01 00:00:00

  • End of life in children with cancer: experience at the pediatric oncology department of the istituto nazionale tumori in Milan.

    abstract:BACKGROUND:Coping with end-stage pediatric cancer patients and the related bereavement is a challenge for all the caregivers involved. PROCEDURE:Forty-seven cancer patients who died in 2006 were assessed as concerns the main place of care in the end stage of their disease, their symptoms, the palliative treatments rec...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.22284

    authors: Beretta S,Polastri D,Clerici CA,Casanova M,Cefalo G,Ferrari A,Luksch R,Massimino M,Meazza C,Podda MG,Spreafico F,Terenziani M,Bellani FF

    更新日期:2010-01-01 00:00:00

  • Patient-reported health status during pediatric cancer treatment.

    abstract:BACKGROUND:Changes in patient function and factors affecting pediatric patients with cancer during treatment are largely unknown. The purpose of this study was to measure patient-reported outcomes (PROs) in children during the initial 6 months of therapy to characterize function and explore factors associated with func...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.26295

    authors: Dobrozsi S,Yan K,Hoffmann R,Panepinto J

    更新日期:2017-04-01 00:00:00

  • Tumor bed proton irradiation in young children with localized medulloblastoma.

    abstract:BACKGROUND:Radiotherapy is often deferred in very young children with medulloblastoma, in favor of more intense chemotherapy and stem cell rescue; however, posterior fossa radiation has been shown to improve overall survival (OS) and event-free survival compared with adjuvant chemotherapy alone. This study was performe...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.27972

    authors: Grewal AS,Li Y,Fisher MJ,Minturn J,Paltin I,Belasco J,Phillips P,Kang T,Lustig RA,Hill-Kayser C

    更新日期:2019-12-01 00:00:00

  • The associations between maternal factors during pregnancy and the risk of childhood acute lymphoblastic leukemia: A meta-analysis.

    abstract:BACKGROUND:Although genetic and environmental factors are considered to be the main causes of acute lymphoblastic leukemia, the associations between maternal factors during pregnancy and the childhood ALL is still unclear. PROCEDURE:In this study, meta-analysis was used. Medline, PubMed, and Web of Science were search...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,meta分析

    doi:10.1002/pbc.25443

    authors: Yan K,Xu X,Liu X,Wang X,Hua S,Wang C,Liu X

    更新日期:2015-07-01 00:00:00

  • EBV lymphoproliferative disease of host origin after haploidentical stem cell transplantation.

    abstract::Post-transplant lymphoproliferative disease (PTLPD), due to the reactivation of Epstein-Barr virus (EBV), is a serious complication. The risk of the disorder increases with T-cell depletion methods, mismatched hematopoietic stem cell transplantation (HSCT), graft-versus-host disease (GVHD), and immunosuppression. In c...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.20710

    authors: Kasow KA,Leung W,Horwitz EM,Woodard P,Handgretinger R,Hale GA

    更新日期:2007-11-01 00:00:00

  • Improving outcomes for high-risk ALL: translating new discoveries into clinical care.

    abstract::High-risk (HR) acute lymphoblastic leukemia (ALL) remains one of the greatest challenges in pediatric oncology. Relapsed ALL is a leading cause of death in young people, and further improvements in outcome will required the development of therapeutic approaches directed against rational therapeutic targets, as escalat...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,评审

    doi:10.1002/pbc.22996

    authors: Hunger SP,Raetz EA,Loh ML,Mullighan CG

    更新日期:2011-06-01 00:00:00

  • Late effects in childhood cancer survivors: a review with a framing effect bias?

    abstract::Most publications report the adverse (negative) health issues in childhood cancer survivors. Presenting information to the newly diagnosed patient in a positive manner is advocated, while noting that recurrence is the most likely adverse event. Re-analysis of population-based studies on life-threatening toxicities fro...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,评审

    doi:10.1002/pbc.22975

    authors: Fryer C

    更新日期:2011-12-15 00:00:00

  • Comparison of PET-CT and conventional imaging in staging pediatric rhabdomyosarcoma.

    abstract:BACKGROUND:Over the past decade, PET-CT has been used to assess rhabdomyosarcoma (RMS) in children. However, the role of PET-CT in staging RMS is unknown. PROCEDURE:Thirty subjects with RMS, median age 7.3 years, underwent PET-CT before therapy. PET-CTs and conventional imaging (CI) were independently reviewed by two ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.24430

    authors: Federico SM,Spunt SL,Krasin MJ,Billup CA,Wu J,Shulkin B,Mandell G,McCarville MB

    更新日期:2013-07-01 00:00:00

  • Outcomes of immunological interventions for mixed chimerism following allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia.

    abstract:BACKGROUND:For children with juvenile myelomonocytic leukemia (JMML) who undergo stem cell transplantation (SCT), the role of immunological interventions including withdrawal of immunosuppressive therapy (IST) and donor lymphocyte infusion (DLI) for treatment of disease recurrence remains uncertain. PROCEDURE:We analy...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.24259

    authors: Inagaki J,Fukano R,Nishikawa T,Nakashima K,Sawa D,Ito N,Okamura J

    更新日期:2013-01-01 00:00:00

  • Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors.

    abstract:BACKGROUND:To determine the maximum-tolerated duration and dose-limiting toxicity of a daily schedule of orally administered cyclophosphamide and topotecan in pediatric patients with recurrent or refractory malignant solid tumors. METHODS:Patients received oral cyclophosphamide (50 mg/m2/dose) in the morning followed ...

    journal_title:Pediatric blood & cancer

    pub_type: 临床试验,杂志文章

    doi:10.1002/pbc.10456

    authors: Bowers DC,Aquino VM,Leavey PJ,Bash RO,Journeycake JM,Tomlinson G,Mulne AF,Haynes HJ,Winick NJ

    更新日期:2004-01-01 00:00:00

  • DICER1 mutations in embryonal rhabdomyosarcomas from children with and without familial PPB-tumor predisposition syndrome.

    abstract::Embryonal rhabdomyosarcoma (ERMS) is the most common childhood sarcoma and is a component of the familial pleuropulmonary blastoma (PPB)-predisposition syndrome. Using the PPB model, we hypothesized that DICER1 mutations would be found in familial and sporadic forms of ERMS. Blood samples from four children with famil...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.24020

    authors: Doros L,Yang J,Dehner L,Rossi CT,Skiver K,Jarzembowski JA,Messinger Y,Schultz KA,Williams G,André N,Hill DA

    更新日期:2012-09-01 00:00:00